12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
The end of the year brought many changes to the labor law. What’s new for employers? We present par...
Read More >
Basic threshold $94 million effective February 27 - Filing thresholds under the Hart-Scott-Rodino A...
Read More >
Market Trends: What You Need to Know - As reflected in the American Bar Association's Private Targe...
Read More >
The Situation: On June 21, 2020, the Saudi Minister of Tourism, Ahmed Al-Khateeb, announced the crea...
Read More >
The Singaporean response to the COVID-19 outbreak has been comprehensive and coordinated. The 18 Feb...
Read More >
On August 14, 2019, the National Labor Relations Board (NLRB) issued a ruling clarifying several man...
Read More >